Anacor Pharmaceuticals
Pharmaceutical ManufacturingView the employees at
Anacor Pharmaceuticals-
T14 Bsa scientist at Anacor Pharmaceuticals
-
Palo Alto, California, United States
-
Rising Star
keyur khalasi student at Anacor Pharmaceuticals-
India
-
Rising Star
Lucy Day VP Finance at Anacor Pharmaceuticals-
Palo Alto, California, United States
-
Rising Star
Theresa Lawson Executive Administrator at Anacor Pharmaceuticals-
Palo Alto, California, United States
-
Rising Star
Overview
Anacor was a biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. Anacor has discovered and is developing five clinical compounds, including its three lead programs: AN2690, a topical antifungal for the treatment of onychomycosis; AN2728, a topical anti-inflammatory PDE-4 inhibitor for the treatment of psoriasis; and GSK 2251052, or GSK '052 (formerly referred to as AN3365), a systemic antibiotic for the treatment of infections caused by Gram-negative bacteria, which has been licensed to GlaxoSmithKline under the companies' research and development agreement. In addition, Anacor is developing AN2718 as a topical antifungal product candidate for the treatment of onychomycosis and skin fungal infections, and AN2898 as a topical anti-inflammatory product candidate for the treatment of psoriasis and atopic dermatitis.
-